Status:
COMPLETED
Cabazitaxel in Relapsed and Metastatic NSCLC
Lead Sponsor:
Hellenic Oncology Research Group
Conditions:
NSCLC
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The investigators propose to study the single agent activity of Cabazitaxel in a Phase II trial of subjects with relapsed or refractory non-small cell lung cancer pretreated with docetaxel, given the ...
Detailed Description
Non small cell lung cancer represents the second most common type of cancer in both men and women in the Western world. The availability of new active regimens in the first line setting has prompted s...
Eligibility Criteria
Inclusion
- Age\>18 years old
- Cytologically or histologically documented NSCLC
- PS 0-2 (WHO scale)
- Measurable disease according to Response Evaluation Criteria in Solid Tumors (at least one measurable lesion)
- Documented disease progression to previous treatment with docetaxel regimen in 1st or 2nd line setting assessed by Response Evaluation Criteria in Solid Tumors with at least one visceral or soft-tissue metastatic lesion.
- Brain metastases are allowed, given that are clinically stable and the patient does not present neurologic symptoms.
- Previous radiotherapy, either in the adjuvant setting or for the treatment of bone metastases, is allowed provided that the measurable lesions are outside the radiation fields. Patients who were irradiated to ≥ 40% of bone marrow are not eligible for the study.
- Patients must have a recent (within 7 days prior to treatment start) biochemical and hematogical assessment as defined by adequate bone marrow (absolute neutrophil count ≥1.5 x 109 cells/L, platelets ≥100 x 109cells/L and hemoglobin ≥9 g/dL), liver (AST \& ALT ≤ 2.5x ULN, total bilirubin within normal range) and renal (serum creatinine \< 1.5 x ULN). If creatinine 1.0 - 1.5 x ULN, creatinine clearance will be calculated according to CKD-EPI formula and patients with creatinine clearance \<60 mL/min should be excluded) function tests
- Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
- Before patient enrollment, written informed consent must be given according to ICH/GCP and national/local regulations.
Exclusion
- Persistence of clinically relevant treatment-related toxicities from previous chemotherapy or radiotherapy.
- Treatment with other investigational drugs or treatment in another clinical trial within the past four weeks before start of treatment or concomitantly with this trial.
- Other malignancy within the past five years other than basal cell skin cancer or carcinoma in situ of the cervix.
- Patient with reproductive potential not implementing accepted and effective method of contraception
- History of severe hypersensitivity reaction (≥grade 3) to polysorbate 80 containing drugs or to docetaxel
- Uncontrolled severe illness or medical condition (including uncontrolled diabetes mellitus, hypertension, heart failure ≤ NYHA II, history of myocardial infarction within the past 6 months, angina, chronic obstructive pulmonary disease (COPD), serious infections requiring systemic antibiotic therapy (e.g. antimicrobial, antifungal, antiviral)
- Concurrent or planned treatment with strong inhibitors or strong inducers of cytochrome P450 3A4/5 (a one week wash-out period is necessary for patients who are already on these treatments) (see Appendix A and B)
- Prior surgery, radiation, chemotherapy, within 4 weeks prior to treatment
- Active grade ≥2 peripheral neuropathy
- Active grade ≥2 stomatitis
Key Trial Info
Start Date :
September 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2013
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT01852578
Start Date
September 1 2012
End Date
August 1 2013
Last Update
September 28 2015
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
"Ag. Georgios" General Hospital of Chania
Chania, Crete, Greece
2
University Hospital of Crete, Dep of Medical Oncology Heraklion, Greece
Heraklion, Crete, Greece
3
"IASO" General Hospital of Athens Athens, Greece
Athens, Greece
4
Air Forces Military Hospital of Athens Athens, Greece
Athens, Greece